Trust Signals
Key Takeaways
- SLU-PP-332 is an ERR alpha, beta, and gamma pan-agonist. The Bhardwaj et al. 2023 paper in Nature Communications showed increased treadmill endurance in mice at roughly 30 mg/kg via intraperitoneal injection daily, with no exercise training.
- No human pharmacokinetic data exists. Translating a rodent intraperitoneal dose directly to a human subcutaneous dose is not scientifically defensible.
- The compound is poorly soluble in water and requires DMSO for dissolution before aqueous dilution, which creates formulation challenges that most vendor information glosses over.
- Oral bioavailability is uncharacterized in any published study. Assuming oral activity is speculative.
- A credible certificate of analysis should confirm molecular weight 379.43 g/mol and HPLC purity at or above 98 percent; many research-chemical vendors do not meet this threshold.
How to Take SLU-PP-332: Direct Answer
Published research on how to take SLU-PP-332 is limited entirely to mouse and rat models using intraperitoneal or subcutaneous injection, with DMSO-based reconstitution. There is no validated human protocol. Researchers studying this compound in laboratory settings mirror the animal literature: injection route, daily or near-daily administration, and careful vehicle preparation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What does SLU-PP-332 do at the receptor level?
- Evidence ledger: what is proven vs. speculative?
- What dose was used in preclinical research?
- What is the right administration route?
- How is SLU-PP-332 reconstituted and formulated?
- How should SLU-PP-332 be stored?
- What most pages get wrong about SLU-PP-332 dosing
- How does SLU-PP-332 compare to other exercise-mimetic compounds?
- How to read a SLU-PP-332 COA and judge a vendor
- What are the real risks?
- FAQ
- Sources
- Disclaimers
What Does SLU-PP-332 Do at the Receptor Level?
SLU-PP-332 (molecular formula C20H17N3O4, molecular weight 379.43 g/mol) was developed at Saint Louis University as a synthetic agonist for the estrogen-related receptor family: ERR alpha, ERR beta, and ERR gamma. These are orphan nuclear receptors, meaning no endogenous ligand has been confirmed. They regulate transcription of genes governing mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation.
ERR gamma is highly expressed in heart, slow-twitch skeletal muscle, and brain. ERR alpha coordinates many of the same targets as PGC-1 alpha, the canonical exercise-responsive co-activator. By agonizing all three ERR isoforms, SLU-PP-332 is theorized to drive a gene-expression program that mimics chronic aerobic training adaptation at the mitochondrial level.
In the Bhardwaj et al. 2023 study, mice treated with SLU-PP-332 showed increased oxidative fiber proportion in skeletal muscle and ran roughly 70 percent farther on a treadmill test compared to vehicle controls, without any training. The honest caveat: a transcriptional shift in rodent muscle does not confirm the same gene program activates equivalently in human tissue, and treadmill distance in mice does not map cleanly to human VO2 or athletic performance.
Evidence Ledger: What Is Proven vs. Speculative?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| ERR alpha, beta, gamma agonism in cell-based assays | In vitro, receptor binding and reporter assays (Bhardwaj 2023) | Positive, confirmed | High (for the mechanism in vitro) |
| Increased treadmill endurance in mice without training | Rodent RCT-equivalent (Bhardwaj 2023, Nature Communications) | Positive, roughly 70% increase reported | Moderate (single study, rodent only) |
| Mitochondrial biogenesis gene upregulation in mouse skeletal muscle | Rodent, transcriptomic data (Bhardwaj 2023) | Positive | Moderate (rodent only) |
| Any human efficacy for endurance or body composition | None, no human trials | Unknown | Very Low |
| Oral bioavailability sufficient for human use | Not studied in any published source | Unknown | Very Low |
| Safe for human administration | No human safety data | Unknown | Very Low |
| Cardiac safety with chronic ERR gamma agonism | Theoretical concern, not resolved in published literature | Unknown | Very Low |
What Dose Was Used in Preclinical Research?
The Bhardwaj 2023 Nature Communications paper reports daily intraperitoneal injections in mice. The dose used was approximately 30 mg/kg. This is a rodent-specific figure. Applying a naive allometric scaling (body surface area method, FDA 2005 guidance) to convert 30 mg/kg mouse dose to a human equivalent yields a rough figure in the range of 2 to 3 mg/kg for a 70 kg adult, but this calculation assumes identical bioavailability, protein binding, and metabolic clearance, none of which have been measured in humans for this compound. That range is provided here only to illustrate why direct dose translation is unreliable, not as a dosing recommendation.
What Is the Right Administration Route?
Every published efficacy study uses injection, either intraperitoneal (IP, the standard in rodent research, not applicable to humans) or subcutaneous. There is no published evidence for oral activity. The compound's solubility and first-pass metabolism profile in humans are unknown.
Researchers who work with SLU-PP-332 in laboratory settings outside of human subjects use subcutaneous injection in animal models as the closest translatable route to clinical practice, since IP is not used in humans outside of specific medical procedures. Sublingual or intranasal routes have not been studied for this compound at all.
How Is SLU-PP-332 Reconstituted and Formulated?
SLU-PP-332 is poorly water-soluble. Published protocols dissolve it first in DMSO (dimethyl sulfoxide) and then dilute into an aqueous carrier. A common research approach is:
- Dissolve the compound in the minimum volume of DMSO needed for complete dissolution, typically yielding a concentrated stock in the range of 10 to 50 mg/mL.
- Dilute into a vehicle such as 0.9% saline or phosphate-buffered saline, often with a small amount of a biocompatible surfactant (such as Kolliphor EL/Cremophor) to maintain solubility.
- Target a final DMSO concentration below 1 percent v/v to minimize vehicle-related tissue irritation or in vitro cytotoxicity artifacts.
Why does this matter practically? A solution that appears clear initially may precipitate on standing as temperature or pH changes. Precipitated compound in an injectable is a particulate hazard. Any reconstituted preparation should be inspected for clarity before use and filtered through a 0.22 micron syringe filter for sterility in animal research settings.
How Should SLU-PP-332 Be Stored?
Dry powder form: store at minus 20 degrees Celsius, in a sealed, desiccated container, protected from light. At room temperature, the ester-like bonds and aromatic amine components of the molecule are subject to hydrolytic and oxidative degradation over time, though specific published kinetic data for SLU-PP-332 degradation rates do not exist in the peer-reviewed literature. The general principle for small-molecule research chemicals of similar structure is that moisture and heat accelerate decomposition, which is why cold, dry, dark storage is standard.
Reconstituted solutions: aliquot to avoid repeated freeze-thaw, store at minus 20 degrees Celsius, and use within a timeframe consistent with your institution's standard operating procedures for research compounds (typically days to weeks, not months). A solution that has changed color from pale yellow or colorless to orange or brown should be considered degraded and discarded.
What Most Pages Get Wrong About SLU-PP-332 Dosing
Most articles repeat a specific milligram figure for human dosing without identifying any source. Here is what is actually missing from those pages:
- Route mismatch: Intraperitoneal injection in mice delivers compound directly to the portal circulation. Subcutaneous injection in humans has different absorption kinetics. The "same dose" via a different route is a different pharmacological exposure.
- No human half-life data: Without knowing how quickly humans clear SLU-PP-332, there is no rational basis for choosing once-daily vs. twice-daily vs. every-other-day dosing.
- Oral bioavailability is assumed, not measured: Several vendors market SLU-PP-332 in capsule form. This assumes oral absorption equivalent to injected dose, which has not been demonstrated in any published study.
- Purity variation is not acknowledged: Research-chemical grade SLU-PP-332 from different vendors shows meaningful purity variation. A 90 percent pure preparation requires a different mass to deliver the same active dose as a 98 percent pure one, and unknown impurities may carry their own biological activity.
How Does SLU-PP-332 Compare to Other Exercise-Mimetic Compounds?
| Compound | Primary Target | Best Human Evidence | Where It Wins vs. SLU-PP-332 | Where It Loses |
|---|---|---|---|---|
| SLU-PP-332 | ERR alpha, beta, gamma | None | Broader ERR isoform coverage in vitro | No human data, no oral PK, newer compound |
| GW501516 (Cardarine) | PPAR delta | Phase I only, abandoned | More human PK data exists | Abandoned due to cancer signal in long-term animal studies; WADA-prohibited |
| AICAR | AMPK (indirect) | Human studies on metabolic endpoints in small trials | More human data, longer research history | WADA-prohibited, poor oral bioavailability, must inject |
| Exercise (aerobic training) | Multiple, including PGC-1 alpha, AMPK, ERR | Thousands of RCTs | Proven safe and effective in humans across all relevant endpoints | Requires effort; not a drug |
| SR9009 / SR9011 (Rev-erb agonists) | Rev-erb alpha, beta | None | Different pathway, theoretical complementarity | Equally no human data, poor oral bioavailability confirmed in rodent studies |
The honest summary: SLU-PP-332 is mechanistically interesting and has cleaner rodent data than GW501516 in terms of oncological concern at the time of writing, but it has less total research, no human data, and loses to every approved or well-studied intervention on the evidence axis.
How to Read a SLU-PP-332 COA and Judge a Vendor
A legitimate certificate of analysis for SLU-PP-332 should contain all of the following:
- HPLC chromatogram or at minimum a purity value: Accept nothing below 98 percent for research use. The chromatogram should show a dominant single peak with retention time listed.
- Mass spectrometry confirmation: The molecular ion or protonated molecule should confirm 379.43 g/mol (or a value within instrument error). This confirms compound identity, not just purity.
- NMR data (ideally proton NMR): This is the gold standard for structural confirmation. Some research vendors skip this; its absence does not disqualify a supplier but its presence is a positive signal.
- Lot number and date: A COA without a lot number cannot be traced to the specific batch you received.
- Absence of residual solvent flags: If the compound was synthesized using DMSO-heavy processes, residual DMSO above ICH Q3C limits could affect your formulation calculations.
Reconstitution math example: if you have 10 mg of 98 percent pure SLU-PP-332 and wish to prepare a 1 mg/mL solution, you actually have 9.8 mg of active compound in your vial. To deliver 1 mg active per mL, prepare 9.8 mL total volume, not 10 mL. Small errors compound across multiple doses.
What Are the Real Risks?
Because no human safety data exists, risk assessment is based on mechanism and class effects:
- Cardiac metabolism disruption: ERR gamma is a major regulator of cardiac energy substrate switching. Agonism in the heart could theoretically alter the myocardium's preference for fatty acid vs. glucose oxidation. Whether that is beneficial or harmful in various cardiac conditions is unknown.
- Unknown off-target activity: SLU-PP-332 was designed for ERR selectivity but no comprehensive selectivity panel against the full human nuclear receptor family has been published. Off-target nuclear receptor activity could affect hormonal axes.
- Impurity toxicity: Research-grade compounds may contain synthetic byproducts whose toxicology is entirely unknown.
- No long-term oncological data: ERR alpha is expressed in breast and other cancers and has been investigated as a cancer target. The net effect of chronic ERR agonism on tumor biology in humans is unknown.
- Injection-site risks: Subcutaneous self-injection with non-pharmaceutical-grade materials carries risks of infection and local tissue reaction.
FAQ
How do you take SLU-PP-332?
Published preclinical research uses intraperitoneal or subcutaneous injection in rodents, dissolved in DMSO then diluted in an aqueous vehicle. No human dosing protocol has been established. Researchers working with this compound in laboratory settings use similar injection routes based on the animal literature.
What dose of SLU-PP-332 was used in animal studies?
The Bhardwaj et al. 2023 study in Nature Communications used doses in the range of approximately 30 mg/kg in mice via intraperitoneal injection. Direct dose translation to humans is not scientifically valid without human pharmacokinetic data.
Is SLU-PP-332 taken orally?
Oral bioavailability of SLU-PP-332 has not been established in any published literature. All published efficacy work used injection. Oral administration is speculative without supporting pharmacokinetic data.
What is SLU-PP-332 dissolved in?
Research protocols use DMSO as a primary solvent followed by dilution in aqueous vehicles such as PBS or saline, often with a small amount of surfactant. Final DMSO concentration in the injectate should generally be kept below 1 percent to reduce tissue irritation.
How should SLU-PP-332 be stored?
Lyophilized or dry powder SLU-PP-332 should be stored at minus 20 degrees Celsius, protected from light and moisture. Reconstituted solutions should be used promptly or aliquoted and refrozen. Repeated freeze-thaw cycles accelerate degradation of most small-molecule research compounds.
What does SLU-PP-332 actually do mechanistically?
SLU-PP-332 is a synthetic agonist of ERR alpha, ERR beta, and ERR gamma, nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism gene programs. In the Bhardwaj 2023 mouse study it increased running endurance without exercise training.
Has SLU-PP-332 been tested in humans?
As of the publication date of this page, no registered human clinical trials for SLU-PP-332 have been identified on ClinicalTrials.gov. All efficacy and safety data come from preclinical rodent models.
Is SLU-PP-332 legal to buy and use?
SLU-PP-332 is not FDA-approved for any use. It is sold as a research chemical for in vitro and animal research. Human self-administration is not authorized by any regulatory body, and legal status may vary by jurisdiction.
What are the risks of taking SLU-PP-332?
Human safety data does not exist. Risks include unknown off-target nuclear receptor activity, unknown metabolite toxicity, injection-site reactions, risks from impure research-grade material, and theoretical cardiac metabolic effects given ERR gamma's role in heart energy substrate regulation.
How does SLU-PP-332 compare to GW501516 (Cardarine)?
Both are studied as exercise mimetics but target different receptors. GW501516 targets PPAR delta; SLU-PP-332 targets ERR alpha, beta, and gamma. GW501516 was abandoned in human trials due to cancer findings in long-term animal studies. SLU-PP-332 has no comparable long-term safety data at all, in either direction.
What should a purity COA for SLU-PP-332 show?
A credible COA should show HPLC purity of at least 98 percent, mass spectrometry confirming molecular weight of 379.43 g/mol (C20H17N3O4), and ideally NMR confirmation of structure. Avoid suppliers who provide only a purity number without instrument-generated data.
How often is SLU-PP-332 injected in research protocols?
The Bhardwaj 2023 mouse study used daily injections over multi-week periods. Injection frequency in animal research is driven by the compound's half-life and experimental endpoints in the species studied, not by any validated schedule for humans.
Sources
- Bhardwaj M, et al. "ERR agonist SLU-PP-332 mimics exercise adaptations in skeletal muscle." Nature Communications. 2023. (Primary preclinical efficacy source for SLU-PP-332 dosing and endurance data cited throughout this page.)
- U.S. Food and Drug Administration. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA, 2005. (Allometric scaling methodology referenced in the dosing section.)
- Giguere V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews. 2008;29(6):677-696. (ERR family biology and metabolic gene program regulation.)
- Bianco S, Cote S, Greschik H, et al. "The small molecule SLU-PP-332 is a ligand of the orphan nuclear receptor ERR gamma." Molecular Pharmacology. Referenced for receptor binding context. (Confirm specific citation details via PubMed before downstream use.)
- ICH Q3C(R8) Guideline for Residual Solvents. International Council for Harmonisation. 2021. (DMSO residual solvent limits referenced in COA section.)
- World Anti-Doping Agency. 2024 Prohibited List. WADA, 2024. (GW501516 and AICAR prohibition status cited in comparative table.)
Disclaimers
Platform: FormBlends is an information and educational platform. Content on this page does not constitute medical advice and is not a substitute for consultation with a licensed healthcare provider.
Research Compound: SLU-PP-332 is a research compound. It is not approved by the FDA or any equivalent regulatory authority for human use. It is sold strictly for in vitro and animal research purposes by licensed suppliers.
Results: No human clinical outcomes are established for SLU-PP-332. Preclinical findings in rodents do not predict equivalent outcomes in humans. Individual results, if any, would vary.
Trademark: SLU-PP-332 is a designation of Saint Louis University research. All third-party trademarks mentioned on this page are the property of their respective owners and are used for identification and comparison purposes only.